Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy.
- Author:
Keisei TATE
1
;
Hiroshi YOSHIDA
;
Mitsuya ISHIKAWA
;
Takashi UEHARA
;
Shun ichi IKEDA
;
Nobuyoshi HIRAOKA
;
Tomoyasu KATO
Author Information
- Publication Type:Original Article
- Keywords: Adenocarcinoma; Endometrial Neoplasms; Prognosis; Cytodiagnosis; Chemotherapy, Adjvant
- MeSH: Adenocarcinoma; Cytodiagnosis; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Gynecology; Humans; Institutional Practice; Multivariate Analysis; Obstetrics; Prognosis; Recurrence
- From:Journal of Gynecologic Oncology 2018;29(3):e34-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive type 2 endometrial cancer. Data on prognostic factors for patients with early-stage USC without adjuvant therapy are limited. This study aims to assess the baseline recurrence risk of early-stage USC patients without adjuvant treatment and to identify prognostic factors and patients who need adjuvant therapy. METHODS: Sixty-eight patients with International Federation of Gynecology and Obstetrics (FIGO) stage I–II USC between 1997 and 2016 were included. All the cases did not undergo adjuvant treatment as institutional practice. Clinicopathological features, recurrence patterns, and survival outcomes were analyzed to determine prognostic factors. RESULTS: FIGO stages IA, IB, and II were observed in 42, 7, and 19 cases, respectively. Median follow-up time was 60 months. Five-year disease-free survival (DFS) and overall survival (OS) rates for all cases were 73.9% and 78.0%, respectively. On multivariate analysis, cervical stromal involvement and positive pelvic cytology were significant predictors of DFS and OS, and ≥1/2 myometrial invasion was also a significant predictor of OS. Of 68 patients, 38 patients had no cervical stromal invasion or positive pelvic cytology and showed 88.8% 5-year DFS and 93.6% 5-year OS. CONCLUSION: Cervical stromal invasion and positive pelvic cytology are prognostic factors for stage I–II USC. Patients with stage IA or IB USC showing negative pelvic cytology may have an extremely favorable prognosis and need not receive any adjuvant therapies.
